DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today provided updates on several programs and events relating to Lymphoseek® (technetium Tc 99m tilmanocept) Injection, including a head-to-head clinical study underway at the University of California, San Diego (UCSD).
Help employers find you! Check out all the jobs and post your resume.
